BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18043129)

  • 1. Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.
    Weidenaar AC; de Jonge HJ; Fidler V; ter Elst A; Meeuwsen-de Boer T; Douwes J; Bouma-ter Steege JC; Hählen K; Kamps WA; de Bont ES
    Anticancer Drugs; 2008 Jan; 19(1):45-54. PubMed ID: 18043129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
    Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
    Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584.
    Weidenaar AC; Ter Elst A; Kampen KR; Meeuwsen-de Boer T; Kamps WA; Schuringa JJ; de Bont ES
    Mol Cancer Res; 2013 Apr; 11(4):339-48. PubMed ID: 23393162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
    Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
    Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.
    Yamamoto A; Watanabe H; Sueki H; Nakanishi T; Yasuhara H; Iijima M
    J Dermatol; 2007 Jul; 34(7):419-29. PubMed ID: 17584317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
    Hess-Stumpp H; Haberey M; Thierauch KH
    Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
    Sini P; Samarzija I; Baffert F; Littlewood-Evans A; Schnell C; Theuer A; Christian S; Boos A; Hess-Stumpp H; Foekens JA; Setyono-Han B; Wood J; Hynes NE
    Cancer Res; 2008 Mar; 68(5):1581-92. PubMed ID: 18316624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia.
    Kim JS; Eom JI; Cheong JW; Choi AJ; Lee JK; Yang WI; Min YH
    Clin Cancer Res; 2007 Feb; 13(3):1019-28. PubMed ID: 17289898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
    Thomas AL; Morgan B; Horsfield MA; Higginson A; Kay A; Lee L; Masson E; Puccio-Pick M; Laurent D; Steward WP
    J Clin Oncol; 2005 Jun; 23(18):4162-71. PubMed ID: 15867205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor.
    Imai N; Miwa H; Shikami M; Suganuma K; Gotoh M; Hiramatsu A; Wakabayashi M; Watarai M; Hanamura I; Imamura A; Mihara H; Shitara K; Shibuya M; Nitta M
    Leuk Res; 2009 Dec; 33(12):1650-7. PubMed ID: 19342098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia.
    de Jonge HJ; Weidenaar AC; Ter Elst A; Boezen HM; Scherpen FJ; Bouma-Ter Steege JC; Kaspers GJ; Goemans BF; Creutzig U; Zimmermann M; Kamps WA; de Bont ES
    Clin Cancer Res; 2008 Feb; 14(3):924-30. PubMed ID: 18245556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
    Hos D; Bock F; Dietrich T; Onderka J; Kruse FE; Thierauch KH; Cursiefen C
    Invest Ophthalmol Vis Sci; 2008 May; 49(5):1836-42. PubMed ID: 18436817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.
    Muranyi AL; Dedhar S; Hogge DE
    Exp Hematol; 2009 Apr; 37(4):450-60. PubMed ID: 19302919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
    Giles FJ; List AF; Carroll M; Cortes JE; Valickas J; Chen BL; Masson E; Jacques C; Laurent D; Albitar M; Feldman EJ; Roboz GJ
    Leuk Res; 2007 Jul; 31(7):891-7. PubMed ID: 17560285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
    Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
    Drevs J; Müller-Driver R; Wittig C; Fuxius S; Esser N; Hugenschmidt H; Konerding MA; Allegrini PR; Wood J; Hennig J; Unger C; Marmé D
    Cancer Res; 2002 Jul; 62(14):4015-22. PubMed ID: 12124335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity.
    Bonci D; Musumeci M; Coppola V; Addario A; Conticello C; Hahne M; Gulisano M; Grignani F; De Maria R
    Haematologica; 2008 Dec; 93(12):1899-902. PubMed ID: 18838478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.